Skip to main content
TipRanks
Go Ultimate75% OFF

Voyageur Pharmaceuticals (VM) AI Stock Analysis

21 Followers
TSE:VM

Voyageur Pharmaceuticals

(TSXV:VM)

Select Model
Rating:40Underperform
Price Target:CAD 0.11â–¼(-0.87% Downside)
Action:downgraded
Date:11/04/26

Voyageur Pharmaceuticals scores near the low end of the range, driven primarily by financial performance: virtually no revenue, widening losses of roughly $3.2M, and an accelerating ~$3.1M annual cash burn that leaves only about a year of runway and a high likelihood of further dilution. The debt-free balance sheet is a genuine positive but cannot offset the absence of profitability or cash generation. Technicals reinforce the caution, with the shares trading below all major moving averages on negative MACD and subdued momentum readings. Valuation provides no cushion given negative earnings and no dividend. This is a speculative, financing-dependent situation whose outcome hinges on future project execution rather than current fundamentals.

Positive Factors
Low Financial LeverageVery low leverage reduces immediate financial risk and preserves flexibility for Voyageur to fund project development or absorb operating volatility. The limited debt burden also avoids substantial interest pressure while the company works toward commercial scale and improved profitability.
Negative Factors
Persistent UnprofitabilityDeep losses and negative gross profit show that the current revenue base is not covering the cost structure. This weak profitability can erode the equity base over time and indicates that meaningful commercial scaling or expense improvement is still required before earnings become durable.

Voyageur Pharmaceuticals (VM) vs. iShares MSCI Canada ETF (EWC)

-60%-40%-20%0%20%40%TSE:VM-23.33%EWC+11.69%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
CAD 20.25M
Dividend Yield
―
Average Volume (3M)
117.38K
Price to Earnings (P/E)
-6.8
Beta (1Y)
0.19
Revenue Growth
360.63%
EPS Growth
14.21%
Country
Canada
Employees
49
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Voyageur Pharmaceuticals Business Overview & Revenue Model

Company Description

Voyageur Pharmaceuticals Ltd. specializes in the creation of mineral-based active pharmaceutical ingredients (APIs). The company aims to produce radiocontrast agents utilizing barium and iodine, along with pharmaceutical products derived from bromine...

Voyageur Pharmaceuticals Financial Statement Overview

Summary

Fundamentals are very weak. Voyageur remains effectively pre-commercial, with only ~$51K of TTM revenue against a ~$3.2M net loss and negative gross profit, producing deeply negative margins and a return on equity near -193%. Cash flow is the biggest risk: operating and free cash flow were both roughly -$3.1M, with the burn accelerating more than 200% versus the prior period and no self-sustaining cash generation. The sole bright spot is a clean, essentially debt-free balance sheet (debt-to-equity ~0.01) with equity rebuilt to ~$4.2M via share issuance, but that equates to only about a year of runway and implies further dilution risk.

Income Statement

8Very Negative

Balance Sheet

42Neutral

Cash Flow

9Very Negative
Financial statement breakdown
BreakdownTTMFeb 2026Feb 2025Feb 2024Feb 2023Feb 2022
Income Statement
Total Revenue50.85K11.69K0000
Gross Profit-1.99M-1.22M-1,570-2,185-2,908-2,246
EBITDA-3.16M-3.53M-1.71M-1.22M-1.74M-2.05M
Net Income-3.16M-3.53M-1.71M-1.40M-1.75M-2.05M
Balance Sheet
Total Assets4.99M3.11M2.60M2.16M2.10M2.57M
Cash, Cash Equivalents and Short-Term Investments1.81M267.05K165.57K2,08531.56K812.97K
Total Debt40.00K40.00K40.00K40.00K25.52K42.08K
Total Liabilities771.49K1.85M2.15M727.88K630.83K660.64K
Stockholders Equity4.22M1.25M449.96K1.44M1.46M1.91M
Cash Flow
Free Cash Flow-3.12M-2.89M-302.29K-991.25K-2.00M-2.09M
Operating Cash Flow-3.12M-2.89M-302.29K-991.25K-1.72M-1.65M
Investing Cash Flow-226.78K-270.02K-165.96K-174.72K-274.15K-432.08K
Financing Cash Flow4.22M3.26M631.73K1.14M1.21M2.90M

Voyageur Pharmaceuticals Technical Analysis

Technical Analysis SentimentNegative
Last Price0.12

Price Trends

50DMA0.14Negative
100DMA0.14Negative
200DMA0.13Negative

Market Momentum

MACD-0.00Positive
RSI40.84Neutral
STOCH8.33Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:VM, the sentiment is Negative. The current price of 0.12 is below the 20-day moving average (MA) of 0.12, below the 50-day MA of 0.14, and below the 200-day MA of 0.13, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 40.84 is Neutral, neither overbought nor oversold. The STOCH value of 8.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:VM.

Voyageur Pharmaceuticals Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

TSE:VM against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TSE:LABSTSE:LABS55NeutralCAD 23.49M-8.46-7.66%―-9.31%66.84%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TSE:ROMJTSE:ROMJ49NeutralCAD 22.64M-5.03-10.97%―16.91%-244.25%
TSE:AVCNTSE:AVCN48NeutralCAD 11.42M-3.86-65.40%―-3.32%-34.15%
TSE:INNOTSE:INNO45NeutralCAD 8.05M-6.01-19.37%―-19.20%42.54%
TSE:VMTSE:VM40UnderperformCAD 26.17M-6.80-193.11%―360.63%14.21%
TSE:PCLOTSE:PCLO39UnderperformCAD 8.41M-2.4128.59%―0.90%57.73%

* Healthcare Sector Average

Performance Comparison

0%100%200%TSE:VMTSE:LABSTSE:PCLOTSE:ROMJTSE:AVCNTSE:INNODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TSE:VM and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TSE:VMVoyageur Pharmaceuticals Ltd.0.12-0.03-17.86%
TSE:LABSMedipharm Labs (Otc)0.06-0.01-15.38%
TSE:PCLOPharmacielo0.040.000.00%
TSE:ROMJRubicon Organics 0.34-0.11-25.56%
TSE:AVCNAvicanna Inc0.09-0.15-64.58%
TSE:INNOInnocan Pharma Corporation1.79-11.00-86.00%

Voyageur Pharmaceuticals Corporate Events

Business Operations and StrategyPrivate Placements and Financing

Voyageur Pharmaceuticals Converts Debt to Equity to Preserve Cash and Advance Contrast Media Strategy

Positive
Oct 2, 2026

Voyageur Pharmaceuticals has completed a shares-for-debt settlement totaling $192,300, issuing common shares at a deemed price of $0.155 to an officer and other creditors in order to preserve cash resources. The transaction, which received final acce...

Business Operations and StrategyPrivate Placements and Financing

Voyageur Pharmaceuticals Converts Debt to Equity to Preserve Cash

Positive
Sep 24, 2026

Voyageur Pharmaceuticals Ltd., a Canadian developer of barium and iodine contrast media for medical imaging, is pursuing a vertically integrated model in the radiology drug market. Leveraging its fully owned Frances Creek barium sulfate resource and...

Business Operations and Strategy

Voyageur advances high-purity iodine extraction with field pilot plans

Positive
Aug 10, 2026

Voyageur Pharmaceuticals has advanced its proprietary Mueller iodine extraction process, achieving laboratory production of iodine at 99.8% purity with overall recovery above 90%. The company has established a dedicated lab and fabrication site in Ho...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 04, 2026